celecoxib has been researched along with Heart Failure in 19 studies
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens." | 9.10 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002) |
| "Celecoxib cardiotoxicity was manifested by significant increases in the LDH, Tn-T, TNF-α, CK-MB, SBP, HR (p < 0." | 7.85 | Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model. ( Ahmad, S; Dubey, K; Fahim, M; Kohli, K; Panda, BP, 2017) |
| "To compare the risk of death and recurrent congestive heart failure in elderly patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs (NSAIDs) and to determine whether there are class differences between celecoxib and rofecoxib." | 7.73 | Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. ( Hudson, M; Pilote, L; Richard, H, 2005) |
| "The psoriatic arthritis was treated with celecoxib and multiple sclerosis with fingolimod." | 5.38 | A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart? ( Cocco, G, 2012) |
| " This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens." | 5.10 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002) |
| "Celecoxib cardiotoxicity was manifested by significant increases in the LDH, Tn-T, TNF-α, CK-MB, SBP, HR (p < 0." | 3.85 | Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model. ( Ahmad, S; Dubey, K; Fahim, M; Kohli, K; Panda, BP, 2017) |
| "To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population." | 3.74 | Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007) |
| "Nonsteroidal antiinflammatory drugs (NSAIDs) as a class have been shown to increase the risk of congestive heart failure (CHF) compared with celecoxib." | 3.74 | Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect? ( Hudson, M; Pilote, L; Rahme, E; Richard, H, 2007) |
| "To compare the risk of death and recurrent congestive heart failure in elderly patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs (NSAIDs) and to determine whether there are class differences between celecoxib and rofecoxib." | 3.73 | Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. ( Hudson, M; Pilote, L; Richard, H, 2005) |
| "These findings suggest a higher risk of admission for congestive heart failure in users of rofecoxib and non-selective NSAIDs, but not celecoxib, relative to non-NSAID controls." | 3.72 | Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. ( Austin, PC; Juurlink, DN; Kopp, A; Laupacis, A; Lee, DS; Mamdani, M; Naglie, G; Rochon, PA; Stukel, TA, 2004) |
| "To determine the costs of heart failure in hypertensive patients receiving celecoxib, rofecoxib, and nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice." | 3.71 | Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. ( Burke, TA; Henderson, SC; von Allmen, H; Whelton, A; Zhao, SZ, 2002) |
| "The psoriatic arthritis was treated with celecoxib and multiple sclerosis with fingolimod." | 1.38 | A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart? ( Cocco, G, 2012) |
| " Inhibition of COX-2 has been associated with the therapeutic effects of NSAIDs, whereas inhibition of COX-1 is believed to be the cause of the adverse gastrointestinal effects associated with NSAID therapy." | 1.31 | A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. ( Arellano, FM; Lejkowith, J; Reynolds, MW; Whelton, A; Zhao, SZ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (68.42) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ungprasert, P | 1 |
| Srivali, N | 1 |
| Kittanamongkolchai, W | 1 |
| Ahmad, S | 1 |
| Panda, BP | 1 |
| Kohli, K | 1 |
| Fahim, M | 1 |
| Dubey, K | 1 |
| Raynauld, JP | 1 |
| Martel-Pelletier, J | 1 |
| Beaulieu, A | 1 |
| Bessette, L | 1 |
| Morin, F | 1 |
| Choquette, D | 1 |
| Haraoui, B | 1 |
| Abram, F | 1 |
| Pelletier, JP | 1 |
| von Haehling, S | 1 |
| Stepney, R | 1 |
| Anker, SD | 1 |
| Bäck, M | 1 |
| Yin, L | 1 |
| Ingelsson, E | 1 |
| Cocco, G | 1 |
| Whelton, A | 3 |
| White, WB | 1 |
| Bello, AE | 1 |
| Puma, JA | 1 |
| Fort, JG | 1 |
| Zhao, SZ | 2 |
| Burke, TA | 1 |
| von Allmen, H | 1 |
| Henderson, SC | 1 |
| Cheng, TO | 1 |
| Weaver, A | 1 |
| Alderman, M | 1 |
| Sperling, R | 1 |
| Mamdani, M | 1 |
| Juurlink, DN | 1 |
| Lee, DS | 1 |
| Rochon, PA | 1 |
| Kopp, A | 1 |
| Naglie, G | 1 |
| Austin, PC | 1 |
| Laupacis, A | 1 |
| Stukel, TA | 1 |
| Hudson, M | 2 |
| Richard, H | 2 |
| Pilote, L | 2 |
| Tegeder, I | 1 |
| Geisslinger, G | 1 |
| Varas-Lorenzo, C | 1 |
| Maguire, A | 1 |
| Castellsague, J | 1 |
| Perez-Gutthann, S | 1 |
| Valat, JP | 1 |
| Deray, G | 1 |
| Héloire, F | 1 |
| Rahme, E | 1 |
| Jacobshagen, C | 1 |
| Grüber, M | 1 |
| Teucher, N | 1 |
| Schmidt, AG | 1 |
| Unsöld, BW | 1 |
| Toischer, K | 1 |
| Nguyen, VP | 1 |
| Maier, LS | 1 |
| Kögler, H | 1 |
| Hasenfuss, G | 1 |
| McGettigan, P | 1 |
| Han, P | 1 |
| Jones, L | 1 |
| Whitaker, D | 1 |
| Henry, D | 1 |
| Reynolds, MW | 1 |
| Lejkowith, J | 1 |
| Arellano, FM | 1 |
3 reviews available for celecoxib and Heart Failure
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: A systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Progression; Heart Failure; Humans; Lact | 2015 |
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Topics: Cardiovascular Diseases; Celecoxib; Cell Proliferation; Clinical Trials as Topic; Cyclooxygenase Inh | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2006 |
1 trial available for celecoxib and Heart Failure
| Article | Year |
|---|---|
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; | 2002 |
15 other studies available for celecoxib and Heart Failure
| Article | Year |
|---|---|
Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model.
Topics: Animals; Cardiotoxicity; Celecoxib; Disease Models, Animal; Folic Acid; Heart Failure; Male; Random | 2017 |
An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Cohort Studies; Cycl | 2010 |
Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference.
Topics: Anabolic Agents; Animals; Appetite Stimulants; Cachexia; Celecoxib; Congresses as Topic; Drug Therap | 2010 |
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Topics: Atrial Fibrillation; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic | 2012 |
A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?
Topics: Arthritis, Psoriatic; Atrial Fibrillation; Autoimmune Diseases; Celecoxib; Cyclooxygenase Inhibitors | 2012 |
Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase | 2002 |
No success with the SUCCESS trial.
Topics: Abbreviations as Topic; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celecoxib; | 2003 |
Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Cycloox | 2003 |
Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase Inhibitors; | 2004 |
Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Celecoxib; Cohort Studies; Cyclooxyge | 2005 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D | 2007 |
Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; C | 2007 |
Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction.
Topics: Animals; Blood Pressure; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Celecoxib; Cyclooxyg | 2008 |
Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; C | 2008 |
A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
Topics: Acute Kidney Injury; Angiotensin Amide; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxy | 2001 |